Navigation Links
Early Detection of Ovarian Cancer Moves Closer
Date:5/20/2010

Step-wise strategy based on blood test was nearly 100% accurate in older women, study found

THURSDAY, May 20 (HealthDay News) -- A step-wise approach accurately spots early stage ovarian cancer in older women at average risk for the disease, new research suggests.

This cancer is known as a silent killer because it is often diagnosed too late to be successfully treated. Scientists have long sought a reliable method of early detection.

The "Risk of Ovarian Cancer Algorithm" (ROCA), which uses a mathematical model, is geared specifically to postmenopausal women at average risk for the disease.

The findings will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), being held next month in Chicago, but were released to reporters at a special news briefing Thursday.

"This ROCA algorithm represents yet another example of personalized medicine. This is personalized towards a screening strategy for a vicious cancer," explained Dr. Douglas W. Blayney, ASCO president, professor of internal medicine at the University of Michigan Medical School and medical director of the Comprehensive Cancer Center at the University of Michigan.

However, experts are awaiting the results of a much larger trial, due out in 2015, before recommending this as routine procedure.

"This is not practice-changing at this time," said study lead author Dr. Karen Lu, professor of gynecologic oncology at the University of Texas M.D. Anderson Cancer Center.

"Ovarian cancer is the most lethal gynecologic cancer and the fourth leading cause of death in cancer in women," Lu said. "Over 75 percent of cases present with advanced-stage disease, when the cure rate is less than 30 percent. There is no effective screening method at the current time."

Measuring levels of a blood protein called CA-125 can help detect ovarian cancer, but the marker is far less than perfect.

This study involved more than 3,200 postmenopausal women, aged 50 to 74, who had not had ovarian cancer themselves and who had no significant family history of breast or ovarian cancer.

The women started off getting a CA-125 blood test every year. If the test indicated low risk, the women could wait another year before their next test.

If levels were elevated, putting them in an intermediate-risk category, however, the women were scheduled for a follow-up test in three months.

If that test was also high, the women were considered high risk and underwent transvaginal sonography (TVS) or ultrasound, and were referred to a gynecologic oncologist, who decided whether or not surgery was needed.

Over the nine years of the trial, 6.8 percent of the volunteers were bumped up to the three-month CA-125 test group, while only 1 percent were referred to TVS and a cancer specialist.

In total, eight of the more than 3,200 women underwent the recommended surgery. Three of those had invasive early-stage cancer (the three had undergone three years of annual CA-125 testing before moving to the next group), two had "borderline" ovarian tumors and the remaining three had benign ovarian tumors.

The specificity of the ROCA method was 99.7 percent, meaning there were virtually no false-positives, the team noted.

No women with invasive ovarian cancer were missed by the test, Lu said.

If results of the larger ROCA trial, currently underway in Britain, are encouraging, ROCA may be coming to a doctor's office in the not too distant future, "part of the routine health exam for postmenopausal women," Blayney said.

More information

Find out more on ovarian cancer at the U.S. National Cancer Institute.



SOURCES: May 20, 2010 news conference with Karen Lu, M.D., professor of gynecologic oncology, The University of Texas M.D. Anderson Cancer Center, and Douglas W. Blayney, M.D., ASCO president, professor of internal medicine, University of Michigan Medical School and medical director, Comprehensive Cancer Center, University of Michigan; study abstract


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
2. New Hope for Early Detection of Autism
3. Preschool depression: The importance of early detection of depression in young children
4. Suntricity Power Stations Report Nearly 100% Percent Uptime Suntricity Power Stations using AC power more reliable than standard sun powered solar systems
5. Drug in new class of targeted therapies shows early promise against blood-related cancers
6. Early Treatment With Clot-Busting Drug Best After Stroke
7. Calcium in early life may prevent obesity later
8. Infectious diseases caused two-thirds of the nearly 9 million child deaths globally in 2008
9. JCI online early table of contents: May 17, 2010
10. Medical costs of cancer have nearly doubled over the past 2 decades
11. Whole body MRI is highly accurate in the early detection of breast cancer metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
(Date:9/21/2017)... ... ... Bill Howe Plumbing’s mission is to create an employee friendly company, provide ... over 37 years, they have operated with their mission at the foundation and have ... They were chosen as the Best San Diego plumber in 2016, named a Top ...
(Date:9/21/2017)... Renton, WA (PRWEB) , ... September 21, 2017 ... ... inspection technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 ... need of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... 21, 2017 , ... Preora Diagnostics Inc. , a ... has received two prestigious recognitions that acknowledge the promise of its PWS Nanoctyology ... has been named a Top 100 Finalist for the 16th annual Chicago Innovation ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017 Caris Life Sciences, a leading ... promise of precision medicine, today announced results from ... its molecular profiling approach in guiding therapeutic strategies ... plus (CGP+) with Caris Molecular Intelligence ® ... molecular level, leading to more therapeutic options and ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: